Johnson & Johnson Vision announced today that it received Health Canada approval for its Acuvue Theravision drug-eluting contact lens.
Jacksonville, Fla.-based J&J Vision’s Acuvue Theravision with Ketotifen is touted as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery. The company received Japanese approval for the lens last month.
Get the full story at our sister site, Drug Delivery Business News.
Johnson & Johnson Vision (NYSE:JNJ) announced today that it received FDA 510(k) clearance and CE mark for its Veritas vision system.
Santa Ana, Calif.–based Johnson & Johnson Vision’s next-generation Veritas phacoemulsification system is designed to allow surgeons to guide through any lens density with less surge and more stability. It also incorporates advancements in ergonomics to enhance usability during cataract surgery, according to a news release.
Veritas’ approvals in the U.S. and Europe follow recent FDA nods for J&J Vision’s Tecnis Eyhance and Tecnis Eyhance Toric II intraocular lens for treating cataract patients, the company said.
Johnson & Johnson Vision intends to begin the full commercial launch of the Veritas system around the globe later this year, the company said.
“While the phacoemulsification technique has been used successfully for decades, ease of use continues to be the unmet need wi…
Johnson & Johnson (NYSE:JNJ) Vision announced today that it entered into a strategic collaboration with Menicon for contact lens development.
J&J Vision and Menicon are partnering to bring forward a novel portfolio of products and services to manage the progression of myopia, sometimes known as “nearsightedness,” in children, according to a news release.
Menicon is set to manufacture therapeutic contact lenses designed to help manage the progression of myopia in children, while J&J Vision will be responsible for expanding the availability of the lenses around the world.
“For decades, Johnson & Johnson Vision has invested in research collaborations with academic centers, research institutes and leading global health organizations who share our vision of leading with science to reshape the future of myopia and eye health,” J&J Vision Care global president Peter Menziuso said in the release. “Our collaboration with Menicon ma…